These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 17929076

  • 1. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [Abstract] [Full Text] [Related]

  • 4. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
    Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E.
    Clin Exp Rheumatol; 2010 Jul; 28(5):661-8. PubMed ID: 20822711
    [Abstract] [Full Text] [Related]

  • 8. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.
    Clin Exp Rheumatol; 2008 Jul; 26(3):401-7. PubMed ID: 18578960
    [Abstract] [Full Text] [Related]

  • 9. Biological and clinical effects of anti-TNFalpha treatment.
    Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M.
    Autoimmun Rev; 2007 Nov; 7(1):35-41. PubMed ID: 17967723
    [Abstract] [Full Text] [Related]

  • 10. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 11. [Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies].
    Cavazzana I, Franceschini F, Danieli E, Frassi M, Vianelli M, Gorla R, Airò P, Cattaneo R.
    Reumatismo; 2005 Dec; 57(4):267-72. PubMed ID: 16380754
    [Abstract] [Full Text] [Related]

  • 12. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases.
    Caramaschi P, Bambara LM, Pieropan S, Tinazzi I, Volpe A, Biasi D.
    Joint Bone Spine; 2009 Jul; 76(4):333-42. PubMed ID: 19539516
    [Abstract] [Full Text] [Related]

  • 13. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 14. Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
    Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M.
    Rheumatol Int; 2010 Feb; 30(4):451-4. PubMed ID: 19506882
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis.
    Fusconi M, Vannini A, Dall'Aglio AC, Pappas G, Bianchi FB, Zauli D.
    Rheumatol Int; 2007 Nov; 28(1):47-9. PubMed ID: 17564711
    [Abstract] [Full Text] [Related]

  • 18. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P.
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [Abstract] [Full Text] [Related]

  • 19. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
    Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O.
    Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
    [Abstract] [Full Text] [Related]

  • 20. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.